Open Forum Infectious Diseases · 2023 · 10 citations · 19 references
Life SciencesImmunologyInfectious DiseasesAutoimmunityClinical ImmunologyImmunopathologyAutoantibodiesAutoantigensAutoimmune Disease PathogenesisAutoimmune DiseasesFatigueInterferon ResponsesInterferon Pathway DefectsInterferon Pathway GenesInterferon-mediated PathologySars-cov-2 InfectionType I Interferon BiomarkersType I Interferon PathwaysType I Interferon ResponsesType I Interferon Signature
Genetic defects in the interferon (IFN) system or neutralizing autoantibodies against type I IFNs contribute to severe COVID-19. Such autoantibodies were proposed to affect post-COVID-19 syndrome (PCS), possibly causing persistent fatigue for >12 weeks after confirmed SARS-CoV-2 infection. In the current study, we investigated 128 patients with PCS, 21 survivors of severe COVID-19, and 38 individuals who were asymptomatic. We checked for autoantibodies against IFN-α, IFN-β, and IFN-ω. Few patients with PCS had autoantibodies against IFNs but with no neutralizing activity, indicating a limited role of type I IFNs in PCS pathogenesis. In a subset consisting of 28 patients with PCS, we evaluated IFN-stimulated gene activity and showed that it did not correlate with fatigue. In conclusion, impairment of the type I IFN system is unlikely responsible for adult PCS.
19
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Paul Bastard, Lindsey B. Rosen, Qian Zhang et al. · Science · 2020 · 2.8K citations · Full text
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Qian Zhang, Paul Bastard, Zhiyong Liu et al. · Science · 2020 · 2.4K citations · Full text
Multiple early factors anticipate post-acute COVID-19 sequelae
Yapeng Su, Dan Yuan, Daniel Chen et al. · Cell · 2022 · 1.2K citations · Full text
Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation
Greta Guarda, Marion Braun, Francesco Staehli et al. · Immunity · 2011 · 926 citations · Full text